波士顿科学公司购买Penumbra14.5B美元, 在投资者的混合反应中提升中风技术。 Boston Scientific to buy Penumbra for $14.5B, boosting stroke tech amid mixed investor reactions.

波士顿科学公司同意以145亿美元的价格收购Penumbra, 每股现金或股票提供374美元, Penumbra股票的股价达到52周高点352美元. Boston Scientific agreed to acquire Penumbra in a $14.5 billion deal, offering $374 per share in cash or stock, sparking Penumbra’s stock to hit a 52-week high of $352. 这次采购预计将于2026年结束,将Penumbra的中风和血管治疗技术与波士顿科学公司的投资组合结合起来,目的是加强其在高增长的医疗设备市场中的地位。 The acquisition, expected to close in 2026, combines Penumbra’s stroke and vascular treatment technologies with Boston Scientific’s portfolio, aiming to strengthen its position in high-growth medical device markets. Penumbra2025年的强劲财政结果,包括14亿美元的收入指导,刺激了投资者的热情,尽管对交易的公平性、内幕出售和股票波动仍然存有疑虑。 Penumbra’s strong 2025 financial results, including revenue guidance of $1.4 billion, fueled investor enthusiasm, though concerns remain over the deal’s fairness, insider selling, and stock volatility. 这笔交易的资金将来自现金和债务,波士顿科学公司预测初步略微稀释,但可长期回收。 The transaction will be funded with cash and debt, with Boston Scientific projecting slight initial dilution but long-term accretion.